Supreme Completes Payment for Option to Purchase Producing Medical Marijuana Facility

APRIL 25, 2014 April 25, 2014, Vancouver, BC – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – CSE) announces that it has paid the option price by way of $150,000 in cash and issued 2,000,000 common shares for the previously announced option with respect to the producing medical marijuana facility in the South Okanagan. […]

Supreme Secures Option to Purchase Producing Medical Marijuana Facility

APRIL 22, 2014 April 22nd, 2014, Vancouver, BC – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – CSE)is pleased to announce that after completion of its due diligence and the completion of other conditions, it has acquired the previously announced option with respect to the producing medical marijuana facility in the South Okanagan […]

Supreme to Trade on the Canadian Securities Exchange

APRIL 21, 2014 April 21st, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – CSE) announces that the Company is moving its listing from the TSX Venture Exchange to the Canadian Securities Exchange (CSE, formerly the CNSX) today under the symbol SL. This move will allow the efficient and seamless transition […]

Supreme Extends Due Diligence and Cancels Private Placement

APRIL 15, 2014 CALGARY, ALBERTA–(Marketwired – April 15, 2014) – Supreme Pharmaceuticals Inc. (the “Company”) (OTCBB:SPRWD)(TSX VENTURE:SL) reports that the parties to the agreement to acquire the South Okanagan producing medical marijuana facility, have mutually agreed upon an extension of the due diligence period to April 29th, 2014. In addition, the Company has cancelled its plans […]

Supreme Enters into Negotiations for an Additional Medical Marijuana Producing Facility

APRIL 14, 2014 April 14th, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – TSX.V) reports that the Company has entered into negotiations with a producing medical marijuana facility to acquire that business. This is in addition to the South Okanagan producing facility currently under evaluation. The parties have agreed to […]

Supreme Extends Due Diligence Period

APRIL 04, 2014 April 4th, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – TSX.V) reports that the parties have extended the due diligence period in respect to the Company’s peviously announced option agreement for an additional 7 business days until April 10, 2014. While due diligence results have been positive […]

Executive Management Visits Producing Facility as Part of Due Diligence

APRIL 01, 2014 April 1st, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – TSX.V) advises that management is currently visiting the producing medical marijuana facility on which the Company may acquire an option to purchase, as part of its due diligence. The facility is located in the south Okanagan and […]

Supreme Updates Option to Purchase Press Release and Announces Private Placement

MARCH 25, 2014 March25th, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – TSX.V) is pleased to announce that the Company has signed a conditional agreement with an arms-length South Okanagan-based company, whereby the Company has the option to purchase its producing medical marijuana business until March 23, 2015 for the […]

Supreme Acquires Option to Purchase producing Medical Marijuana Facility

MARCH 24, 2014 March 24th, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – TSX.V) is pleased to announce that the Company has signed a conditional agreement with an arms-length South Okanagan-based company, whereby the Company has the option to purchase its producing medical marijuana business for up to twelve months […]

Supreme to Evaluate Medical Marijuana Opportunities

MARCH 21, 2014 March21st, 2014, Calgary, AB – Supreme Pharmaceuticals Inc. (the “Company”) (“SL” – TSX.V) is pleased to announce that its continued efforts to secure an exclusive license agreement for a medical device are making significant headway; the Company will continue to keep its shareholders up to date on negotiations. In addition to medical devices, […]